Name: 15663-27-1|cis-Diaminodichloroplatinum(II)|99%
Brand: Ambeed
SKU: A210558
Price: 5.0 USD
Availability: InStock
Rating: 97 (40 reviews)

1
[ 15663-27-1 ]
[ 56-34-8 ]
tetraethylammonium Pt(ammonia)Cl₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In 1,2-dimethoxyethane; at 100℃; for 7h;	I. Preparation of Et4N[PtCl3(NH3)] tetraethylammounium amminetrichloroplatinate; K[PtCl3(NH3)] potassium amminetrichloroplatinate A mixture of cisplatin (8.1 g) and <strong>[56-34-8]tetraethylammonium chloride</strong> (5.64 g) in 300 mL of N,N-dimethylacetamide was heated at 100 C. with bubbling of argon for 7 hours. The resulting dark orange solution was concentrated to a final volume of approximately 50 mL. To this mixture was added a solution of hexane and ethyl acetate (400 mL; 1:1 v/v). The resulting suspension was put in refrigerator (-5 C.) for 14 hours. The light pale yellow solution was then decanted and the orange oil was extracted with 100 mL of deionized water. The yellow precipitate was filtered, and the filtrate was lyophilized to give a yellow solid of pure tetraethylammounium amminetrichloroplatinate. The above platinate was dissolved in 100 mL of deionized water, and acid exchange resin was added. The mixture was stirred for 30 min. and the resin was filtered. The filtrate was concentrated to 10 mL, and 10 mL of saturated KCl solution was added. The resultant solution was put in a refrigerator at 2 C. for 16 hours to give the desired product of potassium amminetrichloroplatinate (orange solid, 2.62 g; 41%). 195Pt NMR delta-1880 ppm. Predicted HRMS for K2PtNH3Cl3: 394.824736; found: 394.824202.
		This coordination complex was synthesized using a previously reported procedure (Giandomenico et al., Inorg. Chem. 34:1015-21 (1995)). A solution of cisplatin (2.34 g) and tetraethylamrmonium chloride (1.66 g) in fresh dimethylacetamide (200 mL) was heated to 100 C with stirring while purging with argon. The temperature was maintained for 7 h, and the solution volume was allowed to reduce to approximately 50 mL by the end of the reaction time. Care was made to prevent prolonged heating above 100 C. to avoid decomposition of the platinum reagent. After completion of the reaction, the reaction solution was allowed to cool to room temperature, 450 mL of a 1:1 hexane:ethyl acetate mixture was added, and the resultant solution cooled at -20 C overnight. This cooling precipitates out an orange product oil, which was easily separated from the supernatant solution. The orange product contains the tetraethylammonium salt of the desired platinum complex, (Et4N)[Pt(NH3)Cl3]. This oil was dissolved in 20 mL of water, and the solution allowed to sit for 30 min to allow for precipitation of unreacted cisplatin. This solution was filtered, and mixed with 50 mL of rinsed acidic Dowex 50W-X8 to affect ion exchange. The solution was again filtered to remove the resin, and the volume of the resultant solution was reduced to 1-2 mL by rotary evaporation. Crystals of K[Pt(NH3)Cl3] were isolated through the addition of a 3 mL of a saturated KCl solution to the ion exchanged [Pt(NH3)Cl3] solution. The resultant mixture was chilled at 5 C for several hours, and afforded orange crystalline K[Pt(NH3)Cl3]. Yield: 2.01 g (69%), 195Pt NMR(H2O): -1743 ppm [Pt(NH3)Cl3]+, FTIR (cm-1, KBr pellet): 3529, 3475, 1626, 1545, 1324, 544, 520.
	In N,N-dimethyl acetamide; at 100℃; for 6h;Inert atmosphere;	All four Pt intermediates were prepared using literature methods [27], with some modifications. To cisplatin (0.468 g,1.56 mmol) and <strong>[56-34-8]tetraethylammonium chloride</strong> (Et4NCl, 0.332 g,1.88 mmol) was added 40 mL of fresh reagent grade DMA. Thesolution was stirred while heating at 100 ± 2 C for 6 h in around-bottom flask, while a slow stream of N2 gas was introduced to the solution by a gas dispersion tube for purging. Fresh DMA was added to maintain the volume and temperature control, but the volume of the reaction mixture was allowed to be reduced to approximately 10 mL by the end of the reaction. After the orange solution obtained was cooled to room temperature (r.t.), it was poured into 90 mL of 1/1 v/v hexane/ethyl acetate and was storedat 15 C overnight. The clear solution was decanted and discardedand an orange oil was obtained when it was warmed to r.t. The orange oil was dissolved with 8 mL of water and the mixture was allowed to stand for 30 min at r.t. to allow complete precipitationof a small amount of unreacted cisplatin. The mixture was then filtered via vacuum filtration; the filtrate contained Et4N[PtCl3NH3].The filtrate solution was stirred with 2.0 g of rinsed Dowex 50-W-X8H+ cation exchange resin for 1 h, the resin was filtered via vacuum filtration, and the volume of the filtrate reduced to approximately 5 mL at r.t. To the yellow/orange filtrate, 0.6 mL of saturated KCl solution was added and the mixture stored and leftto evaporate in the refrigerator (7 C) to slowly obtain orange crystals. Orange crystals collected: 162.9 mg (29.2% yield).

In N,N-dimethyl acetamide; at 100℃; for 8h;

First, potassium trichloroplatinate(II) was synthesized from cisplatin,which was previously obtained from potassium tetrachloroplatinate(II),according to already described procedures [30]. For this, cisplatin and[56-34-8]tetraethylammonium chloride (2 equivalents each) were dissolved in86 mL dimethylacetamide (DMA)/g cisplatin. The reaction mixture washeated at 100 C for 8 h in the dark, under stirring and bubbling N2.During this time, the color of the solution changes fromyellowto orange.Next, the volume was reduced to 30 mL. After cooling, this orange solutionwas added to 500 mL of a hexane/ethyl acetate (1:1) mixture, andthe final solution was maintained overnight at -18 C. After that time,a transparent liquid was decanted and the remaining oil was stirredwith 20 mL of cold water, in order to precipitate the unreacted cisplatin,that was filtered subsequently.

Reference： [1]Patent: US2007/4798,2007,A1 .Location in patent: Page/Page column 7
[2]Patent: US6806289,2004,B1 .Location in patent: Page/Page column 51
[3]Inorganica Chimica Acta,2014,vol. 423,p. 215 - 219
[4]Journal of Inorganic Biochemistry,2016,vol. 165,p. 108 - 118

2
[ 15663-27-1 ]
[ 3483-12-3 ]
Pt(NH₃)2(SCH₂CH(OH)CH(OH)CH₂S) [ No CAS ]

Reference： [1]Inorganica Chimica Acta,1987,vol. 137,p. 125 - 130

3
[ 15663-27-1 ]
[ 56-65-5 ]
4NH₃*2Pt⁽²⁺⁾*2C₅H₄N₅C₅H₈O₄P₃O₉^(4-)*4H⁽¹⁺⁾=((C₅H₄N₅C₅H₈O₄P₃O₉H₂)Pt(NH₃)2)2 [ No CAS ]
2NH₃*Pt⁽²⁺⁾*C₅H₄N₅C₅H₈O₄P₃O₉^(4-)*2H⁽¹⁺⁾=(C₅H₄N₅C₅H₈O₄P₃O₉H₂)Pt(NH₃)2 [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1986,vol. 108,p. 4403 - 4408
[2]Journal of the American Chemical Society,1986,vol. 108,p. 4403 - 4408

4
[ 15663-27-1 ]
[ 7722-84-1 ]
cis,cis,trans-diamminedichlorodihydroxy platinum(IV) [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
90%	at 75℃; for 5h;	0099] Synthesis of c,c,MPt(NH3)2Cl2(OH)2] : Hydrogen peroxide (30 wt%, 60 mL) was added drop wise to a round bottom flask containing <strong>[15663-27-1]cisplatin</strong> (1.0 g, 3.33 mmol). The reaction mixture was heated to 75 C for 5 h. The bright yellow solution was kept at room temperature in the dark for overnight to allow crystallization of the product. Yellow crystals were separated by filtration, washed with cold water and dried to get 1 g of compound. Yield 90%>. IR (KBr) umax (cm-1): 3803 (w), 3515 (w), 3458 (br, OH), 3269 (w), 1582 (s), 1442(s), 1378(s), 1074 (m, Pt-OH), 860 (br), 542 [br, Pt-N(O)]. HRMS m/z Calcd. for Cl2H9N202Pt: (M+H)+ 333.9689. Found 333.9683. Melting Point: 295-300 C.
90%	at 75℃; under 760.051 Torr; for 5h;	Synthesis of Hydrogen peroxide (30 wt%, 60 mL) was added drop wise to a round bottom flask containing <strong>[15663-27-1]cisplatin</strong> (1.0 g, 3.33 mmol). The reaction mixture was heated to 75 C for 5 h. The bright yellow solution was kept at room temperature in the dark for overnight to allow crystallization of the product. Yellow crystals were separated by filtration, washed with cold water, and dried to get 1 g of compound . . i-l Pt{ M Phi( '(OS I ) ·· I. Yield 90%. IR (KBr) vniax (cm"1): 3803 (w), 3515 (w), 3458 (br, OH), 3269 (w), 1582 (s), 1442(s), 1378(s), 1074 (m, Pt-OH), 860 (br), 542 [br, Pt-N(O)]. HRMS m/z Calcd. for Chi I VO : (M I f ) 333.9689. Found 333.9683. Melting Point: 295-300C.
87%	In water; at 60℃; for 12h;	Hydrogen peroxide (30?wt%, 30?mL) was added drop wise to a round bottom flask containing <strong>[15663-27-1]cisplatin</strong> (500.0?mg, 1.67?mmol). The reaction mixture was heated to 60?C for 12?h.The bright yellow solution was kept at room temperature in the dark for overnight to allow crystallization of the product. Yellow crystals were separated by filtration, washed with cold water, and dried to get 485.0?mg of oxoplatin, yield 87%.

75%	With water; at 75℃; for 8h;	In certain embodiments, A-platin is synthesized and purified according to the following (also shown schematically in FIG. 3). Oxoplatin is synthesized from <strong>[15663-27-1]cisplatin</strong> by incubating with hydrogen peroxide for 8 hrs. and purified by precipitating with ice-cold acetone (Yield?75%). 2) Cisplatin-monosuccinate is synthesized by reacting oxoplatin with succinic anhydride in DMSO and precipitated with ice-cold acetone (yield?80%). 3) Subsequently, Cisplatin succinate, and triethylamine is incubated in DMSO for 20 min, and then, N,N?-Dicyclohexylcarbodiimide (DCC) will be added and stirred for 1 hr. To this reaction mixture, Boc-4-Amino-L-phenylalanine is added and stirred overnight. The solid is precipitated and washed three times with ice cold acetone. 4) The Boc group is removed from AT-Platin-Boc by reacting with 10% trifluroacetic acid (TFA) in methanol. 5) AT-Platin is further purified by Flash-chromatography with Hexane-Ethyl acetate gradient. The foregoing method consistently yields AT-Platin up to 96% purity. NMR analysis of <strong>[15663-27-1]cisplatin</strong> and AT-platin are shown in FIG. 1. A mass spectrometric analysis of AT-platin is shown in FIG. 2.
60%	In water; at 60℃;	General procedure: The carbohydrate-conjugated mono-functionalized platinum(IV) prodrugs (B1-B10) were prepared by the reaction of an amide bond from peracetyl rhamnose, mannose and galactose with a propyl amino or ethyl amino linker at the reducing end and a carboxylic function in the Pt(IV) complexes (B11 and B12) (Scheme 2). The key step involved the preparation of oxoplatin B13 and B14 which was reacted successively in water (12mL) with <strong>[15663-27-1]cisplatin</strong> (0.2g) or oxaliplatin (0.2g) and H2O2 (20mL) at 60C with the yield of 60% and 55% respectively. B11 and B12 were prepared from oxoplatin B13 (1equiv) or B14 (1equiv) and succinic anhydride (1equiv) in anhydrous DMSO at room temperature overnight. DMSO was removed under vacuum to afford a yellow oil and the product was washed with acetone and diethylether, and dried in vacuum. The target compounds B11 and B12 were obtained as a pale yellow solid after purification by recrystallization with the yield of 75% and 78% respectively. Finally, to a solution of B11 or B12 (1equiv) in DMF was added a DMF solution containing HATU. The mixture was stirred for 10minat room temperature. A DMF solution containing amines and DIPEA was added to the resulting solution to obtain B1 to B10 in yields of 20-50%, respectively. The mixture was stirred at room temperature for 24h in the dark. The product was characterized using 1H-NMR, 13C-NMR, ESI-MS spectrometry and elemental analysis (see ESI+). And meanwhile, the synthesis methods of A4 and A5 which have been reported by our group recently with an increasing antitumor activities and a potential safety compared with <strong>[15663-27-1]cisplatin</strong> and oxaliplatin are also listed in Scheme 2.
	at 20℃; for 5h;Darkness;	Cisplatin (600 mg, 2 mmol) was placed in a reaction flask,Add 30% hydrogen peroxide 10mL, dark at room temperature for 5h,The hydrogen peroxide was removed by filtration to give a yellow powder of Cisplatin (IV) (NH3) 2- (OH) 2.
	In water; at 70℃; for 2h;Inert atmosphere;	In a 150 mL round-bottom flask, 3 g of <strong>[15663-27-1]cisplatin</strong>, 75 mL of deionized water, and 11.4 mL of hydrogen peroxide (30%) were added, and the reaction was carried out at 70 C. for 2 h under argon atmosphere.The precipitated product was cooled with ice water, filtered by suction, washed with ice water, ethanol, and diethyl ether in that order and dried to give c, c, t-[Pt(NH3)2Cl2(OH)2], denoted as Pt(IV)-(OH). )2-1.
	In water; at 60 - 70℃; for 4h;	oxidizing the compound divalent platinum compound <strong>[15663-27-1]cisplatin</strong> Cis. by hydrogen peroxide at 60 to 70 C,After reacting for 4 hours, a tetravalent <strong>[15663-27-1]cisplatin</strong> compound Oxide-Cis. can be prepared;Dissolving the tetravalent <strong>[15663-27-1]cisplatin</strong> compound Oxide-Cis. (1equiv) and palmitic anhydride (4equiv) in DMF,After reacting at 70 C under nitrogen atmosphere for overnight, the oil pump was drained, and after adding methylene chloride to precipitate a solid,The compound Cis(IV)-COOH can be prepared by washing with chloroform, diethyl ether or the like;Mixing the solution of Cis(IV)-COOH in DMF with 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate in DMF for 10 minutes. after that,Further, a mixture of peracetylated glucosamine and N,N-diisopropylethylamine in DMF was added, and the mixture was reacted at room temperature for 24 hours to obtain 5f1.5f1 was dissolved in an appropriate amount of methanol, and 4M HCl was slowly added dropwise for 48 hours to remove the Boc protecting group to obtain the final product.
	In water; at 75℃; for 5h;	H2O2 (60 mL, 30% w/v) was added to cisdiamminedichloroplatinum(II) (1 g, 3.3 mmol). The mixturewas stirred for 5 h at 75 C. The resulting yellow solutionwas kept overnight to crystallize. The precipitate was filteredand washed with cold water, ethanol, and diethyl ether, thendried in vacuum.

Reference： [1]Chemical Communications,2020,vol. 56,p. 3069 - 3072
[2]Dalton Transactions,2018,vol. 47,p. 8268 - 8282
[3]Patent: WO2015/89389,2015,A1 .Location in patent: Paragraph 0099
[4]Patent: WO2016/144889,2016,A1 .Location in patent: Page/Page column 4; 37
[5]Journal of Inorganic Biochemistry,2019,vol. 193,p. 133 - 142
[6]Journal of Medicinal Chemistry,2019,vol. 62,p. 4543 - 4554
[7]Dalton Transactions,2019,vol. 48,p. 5308 - 5314
[8]Molecular Pharmaceutics,2015,vol. 12,p. 4466 - 4477
[9]Journal of Thermal Analysis and Calorimetry,2010,vol. 102,p. 499 - 503
[10]Patent: US2017/239361,2017,A1 .Location in patent: Paragraph 0080
[11]European Journal of Medicinal Chemistry,2017,vol. 128,p. 45 - 55
[12]Chemistry - A European Journal,2014,vol. 20,p. 8942 - 8947
[13]Biomaterials,2018,vol. 177,p. 67 - 77
[14],1939,vol. 23,p. 653 - 657
[15]Zeitschrift fur anorganische Chemie,1926,vol. 151,p. 253 - 268
[16]Inorganic Chemistry,1996,vol. 35,p. 1709 - 1711
[17]Zeitschrift fur anorganische Chemie,1926,vol. 151,p. 263 - 268
[18]Gmelin Handbuch der Anorganischen Chemie,Gmelin Handbook: Pt: MVol.D, 254, page 557 - 559
[19]Journal of Materials Chemistry B,2013,vol. 1,p. 2829 - 2836
[20]Inorganic Chemistry,2013,vol. 52,p. 9915 - 9920
[21]Izvestia Sektora platiny i drugih blagorodnyh metallov.,1927,vol. 5,p. 85 - 101
[22]Chemical Communications,2014,vol. 50,p. 7427 - 7430
[23]Journal of the American Chemical Society,2014,vol. 136,p. 8790 - 8798
[24]Biomacromolecules,2015,vol. 16,p. 105 - 115
[25]Journal of Materials Chemistry B,2015,vol. 3,p. 8203 - 8211
[26]Journal of the American Chemical Society,2015,vol. 137,p. 14854 - 14857
[27]Dalton Transactions,2016,vol. 45,p. 11830 - 11838
[28]International Journal of Nanomedicine,2017,vol. 12,p. 955 - 968
[29]Dalton Transactions,2017,vol. 46,p. 14174 - 14185
[30]Patent: CN107417752,2017,A .Location in patent: Paragraph 0078; 0079; 0080; 0084; 0112
[31]Biomaterials,2018,vol. 156,p. 121 - 133
[32]Biomaterials,2018,vol. 155,p. 112 - 123
[33]Patent: CN107952079,2018,A .Location in patent: Paragraph 0052
[34]Journal of Materials Chemistry B,2018,vol. 6,p. 8137 - 8147
[35]Patent: CN109293702,2019,A .Location in patent: Paragraph 0078-0083; 0103-0108
[36]Dalton Transactions,2019,vol. 48,p. 10537 - 10546
[37]Chemical Papers,2020,vol. 74,p. 2733 - 2741

5
[ 15663-27-1 ]
[ 75-05-8 ]
{Pt<amc><aCl>}Cl [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
76.2%	With hydrogenchloride; In acetonitrile; for 2h;Reflux;	As shown in the above chemical formula,Weigh 60 mg of <strong>[15663-27-1]cisplatin</strong> (0.2 mmol),Add to 6mL of dilute hydrochloric acid pH 4,Add 2 mL of acetonitrile to the solution.Stir well.Heat the solution back to reflux,Until the yellow suspension became a colorless, clear solution (2h).The solution was spun dry to a yellow solid residue.The solid residue solution was treated with 3 mL of dry anhydrous methanol.A yellow suspension was obtained.The solution was filtered through a microporous membrane.The filtrate was slowly dropped into 60 mL of dry anhydrous ether.A large amount of white precipitate is formed.Stir the suspension for 2 h.filter,The filter cake was washed with a small amount of ether.Vacuum drying,A white solid powder P1' is obtained,52 mg, yield 76.2%.

Reference： [1]Patent: CN110128477,2019,A .Location in patent: Paragraph 0042; 0049; 0050
[2]Chemical Communications,2013,vol. 49,p. 2415 - 2417
[3]Izvestia Sektora platiny i drugih blagorodnyh metallov.,1939,vol. 16,p. 57 - 64

6
[ 1123-40-6 ]
[ 15663-27-1 ]
silver nitrate [ No CAS ]
{Pt₂(NH₃)4(C(O)CH₂C(CH₃)2CH₂C(O)N)2}⁽²⁺⁾*2NO₃^(1-)*H₂O={Pt₂(NH₃)4(C₇H₁₀NO₂)2}(NO₃)2*H₂O [ No CAS ]

Reference： [1]Inorganic Chemistry,1991,vol. 30,p. 3914 - 3919

7
[ 15663-27-1 ]
[ 1820-81-1 ]
[ 85584-97-0 ]

Reference： [1]Koordinatsionnaya Khimiya,1983,vol. 9,p. 237 - 243
Koordinatsionnaya Khimiya,1983,vol. 9,p. 410 - 417

8
[ 15663-27-1 ]
[ 21236-97-5 ]
di(cis-diammine(μ-3-methyl-6-aminouracilato)platinum(II))dinitrate [ No CAS ]

Reference： [1]Koordinatsionnaya Khimiya,1991,vol. 17,p. 265 - 271
Koordinatsionnaya Khimiya,1991,vol. 17,p. 510 - 516

9
[ 1123-40-6 ]
[ 15663-27-1 ]
[ 7631-99-4 ]
{Pt₂(NH₃)4(C(O)CH₂C(CH₃)2CH₂C(O)N)2}⁽²⁺⁾*2NO₃^(1-)*H₂O={Pt₂(NH₃)4(C₇H₁₀NO₂)2}(NO₃)2*H₂O [ No CAS ]

Reference： [1]Inorganic Chemistry,1991,vol. 30,p. 3914 - 3919

10
[ 15663-27-1 ]
[ 932-52-5 ]
[Pt(NH₃)2(C₄N₂H₂O₂(NH₂))]2⁽²⁺⁾*2Cl^(1-)=[Pt(NH₃)2(C₄N₂H₂O₂(NH₂))]2Cl₂ [ No CAS ]

Reference： [1]Koordinatsionnaya Khimiya,1986,vol. 12,p. 466 - 473
Koordinatsionnaya Khimiya,1986,vol. 12,p. 814 - 821

11
[ 15663-27-1 ]
[ 932-52-5 ]
Pt⁽²⁺⁾*NH₃*2C₄N₂H₂O₂(NH₂)^(1-)=[Pt(NH₃)(C₄N₂H₂O₂(NH₂))2] [ No CAS ]

Reference： [1]Koordinatsionnaya Khimiya,1986,vol. 12,p. 466 - 473
Koordinatsionnaya Khimiya,1986,vol. 12,p. 814 - 821

12
[ 41575-94-4 ]
[ 7647-14-5 ]
[ 15663-27-1 ]

Reference： [1]New Journal of Chemistry,2000,vol. 24,p. 1003 - 1008

13
[ 15663-27-1 ]
[ 5445-51-2 ]
[ 1310-65-2 ]
[ 41575-94-4 ]

Reference： [1]Inorganica Chimica Acta,1988,vol. 151,p. 19 - 20

14
[ 15663-27-1 ]
[ 5445-51-2 ]
[ 41575-94-4 ]

Reference： [1]Inorganica Chimica Acta,1988,vol. 151,p. 19 - 20
[2]Inorganica Chimica Acta,1988,vol. 151,p. 19 - 20

15
[ 7647-01-0 ]
[ 41575-94-4 ]
[ 15663-27-1 ]

Reference： [1]New Journal of Chemistry,2000,vol. 24,p. 1003 - 1008

16
[ 41575-94-4 ]
[ 15663-27-1 ]

Reference： [1]Journal of the Chemical Society, Dalton Transactions,1988,p. 2135 - 2140

17
[ 110-86-1 ]
[ 7647-01-0 ]
[ 15663-27-1 ]
[ 15092-07-6 ]

Yield	Reaction Conditions	Operation in experiment
85.6%		Ampyplatin was prepared from <strong>[15663-27-1]cisplatin</strong> using a literature method [24]. Cisplatin (225mg) was dispersed in double distilled H2O (4mL) with ultrasound for 2min. 3M pyridine (750muL) was added and the suspension heated at 60C for 4h with stirring. After cooling down to room temperature, 10M HCl (1mL) was added and the mixture was kept at 80C overnight with stirring. Yellow, needle shaped crystals precipitated at the bottom of the flask. The solution was cooled to 4C for half an hour to allow further precipitation of crystals. The crystals were collected, washed twice with water and ethanol, and dried under vacuum. The total yield of trans-[PtCl2(NH3)(py)] was 232.5mg (85.6%). 15N labeled trans-[PtCl2(15NH3)(py)] was prepared by the same procedure starting from 15N labeled <strong>[15663-27-1]cisplatin</strong>. The 1H-NMR spectrum recorded in d6-acetone shows signals at 8.87 (m, H2 and H6), 7.98 (m, H4), 7.45 (m, H3 and H5), and 3.74ppm (broad, NH3). Elemental analyses for trans-[PtCl2(NH3)(py)] (PtC5Cl2H8N2). Calculated: C, 16.58; H, 2.23; N, 7.74%. Found: C, 16.9; H, 2.76; N, 7.82%.

Reference： [1]Journal of Inorganic Biochemistry,2013,vol. 129,p. 15 - 22
[2]Gmelin Handbuch der Anorganischen Chemie,Gmelin Handbook: Pt: MVol.D, 178, page 391 - 393
[3]Izvestia Sektora platiny i drugih blagorodnyh metallov.,1949,vol. 24,p. 60 - 71

18
[ 1123-40-6 ]
[ 15663-27-1 ]
silver nitrate [ No CAS ]
3Pt⁽²⁺⁾*Pt⁽³⁺⁾*8NH₃*4C(O)CH₂C(CH₃)2CH₂C(O)N^(1-)*5NO₃^(1-)*2H₂O={Pt₄(NH₃)8(C₇H₁₀NO₂)4}(NO₃)5*2H₂O [ No CAS ]

Reference： [1]Inorganic Chemistry,1991,vol. 30,p. 3914 - 3919

19
[ 611-08-5 ]
[ 15663-27-1 ]
[ 2206-27-1 ]
(NH₃)2Pt((C⁽²⁾H₃)2SO)(C₄HO₂(NO₂)N₂H)⁽¹⁺⁾ [ No CAS ]

Reference： [1]Journal of general chemistry of the USSR,1984,vol. 54,p. 801 - 806
J.Gen.Chem.USSR (Engl.Transl.),1984,vol. 54,p. 900 - 905

20
[ 15663-27-1 ]
[ 1122-47-0 ]
[ 75659-39-1 ]

Reference： [1]Inorganic Chemistry,1981,vol. 20,p. 335 - 342

21
[ 1123-40-6 ]
[ 15663-27-1 ]
sodium hexaflorophosphate [ No CAS ]
Pt⁽³⁺⁾*3Pt⁽²⁺⁾*8NH₃*4C₅NH₄O₂(CH₃)2^(1-)*NO₃^(1-)*4PF₆^(1-)*8H₂O=Pt₄(NH₃)8(C₇H₁₀NO₂)4(NO₃)(PF₆)4*8H₂O [ No CAS ]

Reference： [1]Inorganica Chimica Acta,1986,vol. 121,p. L29 - L32

22
[ 15663-27-1 ]
[ 1122-47-0 ]
cis-chlorodiammine(1-methylcytosine-N₃)platinum(II) cloride hydrate [ No CAS ]

Reference： [1]Inorganic Chemistry,1995,vol. 34,p. 1022 - 1029
[2]Inorganic Chemistry,1982,vol. 21,p. 3216 - 3225
[3]Inorganic Chemistry,1981,vol. 20,p. 335 - 342

23
[ 15663-27-1 ]
[ 17902-23-7 ]
[ 157619-72-2 ]

Reference： [1]Russian Journal of Coordination Chemistry,1994,vol. 20,p. 47 - 49
Koordinatsionnaya Khimiya,1993,vol. 19,p. 51 - 53

24
[ 1123-40-6 ]
[ 15663-27-1 ]
{Pt₄(NH₃)8(C(O)(CH₂)2C(CH₃)2C(O)N)4}⁽⁵⁺⁾*5NO₃^(1-)*2H₂O = {Pt₄(NH₃)8(C(O)(CH₂)2C(CH₃)2C(O)N)4}(NO₃)5*2H₂O [ No CAS ]

Reference： [1]Chemistry Letters,1993,p. 597 - 600

25
[ 1123-40-6 ]
[ 15663-27-1 ]
[ 149333-88-0 ]

Reference： [1]Chemistry Letters,1993,p. 597 - 600

26
[ 1123-40-6 ]
[ 15663-27-1 ]
Pt⁽³⁺⁾*3Pt⁽²⁺⁾*8NH₃*4C₅NH₄O₂(CH₃)2^(1-)*5NO₃^(1-)*5H₂O=Pt₄(NH₃)8(C₇H₁₀NO₂)4(NO₃)5*5H₂O [ No CAS ]

Reference： [1]Inorganica Chimica Acta,1986,vol. 121,p. L29 - L32
[2]Inorganica Chimica Acta,1986,vol. 121,p. L29 - L32

27
[ 15663-27-1 ]
[ 5550-12-9 ]
cis-[Pt(NH₃)2(5'-guanosine monophosphateNa₂)2]Cl₂ [ No CAS ]

Reference： [1]Inorganica Chimica Acta,1985,vol. 107,p. 203 - 210
[2]Inorganica Chimica Acta,1998,vol. 273,p. 201 - 203

28
[ 15663-27-1 ]
[ 1122-47-0 ]
cis-chlorodiammine(1-methylcytosine-N₃)platinum(II) cloride hydrate [ No CAS ]
cis-[Pt(NH₃)2(MeCyt)2]Cl₂*xH₂O [ No CAS ]

Reference： [1]Inorganic Chemistry,1982,vol. 21,p. 3210 - 3216

29
[ 15663-27-1 ]
[ 1122-47-0 ]
[ 75936-23-1 ]
[ 80662-70-0 ]
[ 80662-74-4 ]

Reference： [1]Inorganic Chemistry,1982,vol. 21,p. 1936 - 1941

30
[ 611-08-5 ]
[ 15663-27-1 ]
[ 85584-99-2 ]

Reference： [1]Koordinatsionnaya Khimiya,1983,vol. 9,p. 237 - 243
Koordinatsionnaya Khimiya,1983,vol. 9,p. 410 - 417

31
[ 15663-27-1 ]
[ 3211-76-5 ]
Pt(L-selenomethionine)(L-selenomethioninate)⁽¹⁺⁾ [ No CAS ]
[PtCl(CH₃SeCH₂CH₂CH(NH₂)COOH)NH₃]⁽¹⁺⁾ [ No CAS ]
[Pt(CH₃SeCH₂CH₂CH(NH₂)COOH)(CH₃SeCH₂CH₂CH(NH₂)COO)(NH₃)2]⁽¹⁺⁾ [ No CAS ]
2Pt⁽²⁺⁾*2Cl^(1-)*(CH₃SeCH₂CH₂CH(NH₂)COO)^(1-)*4NH₃=[Pt₂Cl₂(CH₃SeCH₂CH₂CH(NH₂)COO)(NH₃)4]⁽¹⁺⁾ [ No CAS ]
2Pt⁽²⁺⁾*Cl^(1-)*OH^(1-)*(CH₃SeCH₂CH₂CH(NH₂)COO)^(1-)*4NH₃=[Pt₂Cl(OH)(CH₃SeCH₂CH₂CH(NH₂)COO)(NH₃)4]⁽¹⁺⁾ [ No CAS ]

Reference： [1]Journal of the Chemical Society. Dalton Transactions (2001),2001,p. 911 - 916

32
[ 1123-40-6 ]
[ 15663-27-1 ]
[Pt₄(NH₃)8(3,3-dimethylglutarimidate)4](NO₃)5 * 2H₂O [ No CAS ]

Reference： [1]Inorganic Chemistry,1995,vol. 34,p. 202 - 208
Inorg. Chem.,

33
[ 15663-27-1 ]
[ 14769-73-4 ]
silver nitrate [ No CAS ]
Pt⁽²⁺⁾*2NH₃*C₁₁H₁₂N₂S*Cl^(1-)*NO₃^(1-)=[Pt(NH₃)2(C₁₁H₁₂N₂S)Cl](NO₃) [ No CAS ]

Reference： [1]Inorganica Chimica Acta,1997,vol. 256,p. 253 - 262

34
[ 15663-27-1 ]
[ 14769-73-4 ]
Pt⁽²⁺⁾*NH₂CH₂CH₂NH₂*C₁₁H₁₂N₂S*2Cl^(1-)=[Pt(NH₂CH₂CH₂NH₂)(C₁₁H₁₂N₂S)Cl]Cl [ No CAS ]

Reference： [1]Inorganica Chimica Acta,1997,vol. 256,p. 253 - 262

35
[ 15663-27-1 ]
[ 17902-23-7 ]
[ 172649-96-6 ]

Reference： [1]Russian Journal of Coordination Chemistry,2002,vol. 28,p. 419 - 422

36
[ 15663-27-1 ]
[ 17902-23-7 ]
[ 462658-05-5 ]

Reference： [1]Russian Journal of Coordination Chemistry,2002,vol. 28,p. 419 - 422

37
[ 15663-27-1 ]
[ 5550-12-9 ]
Na₂[Pt(NH₃)2(guanosine-5'-monophosphate)2] * 3 H₂O [ No CAS ]

Reference： [1]Inorganica Chimica Acta,1996,vol. 248,p. 225 - 230

38
[ 15663-27-1 ]
[ 26042-63-7 ]
[ 494-38-2 ]
[ 638165-23-8 ]

Reference： [1]New Journal of Chemistry,2003,vol. 27,p. 1497 - 1503

39
[ 15663-27-1 ]
[ 494-38-2 ]
silver nitrate [ No CAS ]
[ 638165-22-7 ]

Reference： [1]New Journal of Chemistry,2003,vol. 27,p. 1497 - 1503

40
[ 2036-41-1 ]
[ 15663-27-1 ]
silver perchlorate [ No CAS ]
cis-diamminobis(5-methylpyrimidine)platinum(II) perchlorate [ No CAS ]

Reference： [1]Inorganica Chimica Acta,1979,vol. 36,p. 13

41
[ 15663-27-1 ]
[ 6270-46-8 ]
[ 104626-67-7 ]

Reference： [1]Koordinatsionnaya Khimiya,1986,vol. 12,p. 466 - 473
Koordinatsionnaya Khimiya,1986,vol. 12,p. 814 - 821

42
[ 15663-27-1 ]
potassium chloride [ No CAS ]
[ 56-34-8 ]
potassium amminetrichloroplatinate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
3 g		(1) raw materials (1) cis-diaminodichloroplatinum (5.0 g, 0.017 mol),Tetraethylammonium (3.57 g, 1.2 times equivalent) was dissolved in 130 mL of dimethylacetamide and heated under inert gas protection at 105 C for 12 hours.After distilling the solution under reduced pressure to 50 mL,Add 300 mL of cyclohexane and ethyl acetate (1: 1),The suspension was stored at -12 C for 12 hours.The precipitated crystals were filtered and dried under vacuum to give the crude product as an orange solid.Add 50 mL of deionized water, stir at 25 C for 30 minutes, and then filter.The obtained filtrate was put into Dowex 50W-X8 hydrogen ion exchange resin and stirred for 1 hour, and then the filtrate and solid resin were separated by filtration, and the filtrate was concentrated to 5 mL. At 0 C, 2 mL of a saturated potassium chloride solution was added to the concentrated filtrate, and the mixture was stirred at this temperature for 2 hours to obtain the product compound 2 potassium trichloromonoammonium platinum (II) acid (3.0 g).
3 g		Raw material 1 cis-diaminodichloroplatinum (5.0g, 0.017mol),Tetraethylammonium (3.57g, 1.2 times equivalent)Dissolved in 130mL dimethylacetamide,And heated under inert gas at 105 C for 12 hours,After the solution was distilled under reduced pressure to 50 mL, 300 mL of cyclohexane and ethyl acetate (1: 1) were added thereto, and the suspension was stored at -12 C for 12 hours. The precipitated crystals were filtered and dried under vacuum to give the crude product as an orange solid.Add 50 mL of deionized water, stir at 25 C for 30 minutes, and then filter. The obtained filtrate was put into Dowex 50W-X8 hydrogen ion exchange resin and stirred for 1 hour, and then the filtrate and solid resin were separated by filtration, and the filtrate was concentrated to 5 mL. At 0 C, 2 mL of a saturated potassium chloride solution was added to the concentrated filtrate, and the mixture was stirred at this temperature for 2 hours to obtain the product compound 2 potassium trichloromonoammonium platinum (II) acid (3.0 g).

Reference： [1]Inorganica Chimica Acta,2009,vol. 362,p. 4099 - 4109
[2]Patent: CN110423253,2019,A .Location in patent: Paragraph 0034-0038
[3]Patent: CN110330536,2019,A .Location in patent: Paragraph 0036-0040

43
[ 15663-27-1 ]
[ 578-76-7 ]
[ 7732-18-5 ]
cis,cis-[(PtCl(NH₃)2)2(7-methylguanine-N₉)]Cl₂ [ No CAS ]
cis-[Pt(NH₃)2(7-methylguanine-N₉)2]Cl₂*0.5H₂O [ No CAS ]

Reference： [1]Dalton Transactions,2010,vol. 39,p. 73 - 84

44
[ 15663-27-1 ]
[ 578-76-7 ]
cis,cis-[(PtCl(NH₃)2)2(7-methylguanine-N₉)]Cl₂ [ No CAS ]
cis-[Pt(NH₃)2(7-methylguanine-N₉)2]Cl₂ [ No CAS ]

Reference： [1]Dalton Transactions,2010,vol. 39,p. 73 - 84

45
[ 15663-27-1 ]
[ 19668-85-0 ]
JP₀₉₁₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In water; at 60℃;	Example 1; Synthesis of JP09161.; Weigh cisplatin (mw 300) (2 m mole or 600 mg) and place in 150 ml DI water. Mix continuously at ca. 60 C. till cisplatin is all dissolved. 2. Weigh ligand 2 (<strong>[19668-85-0]3-methyl-5-isoxazoleacetic acid</strong>, mw 141.12) (2 m mole or 282 mg) and gradually add it the cisplatin solution until it is all dissolved. Continue heating and mixing for 2 hr. Adding 0.1 N NaOH to raise the pH to about 6 can increase the yield. 3. Cool the aliquot and filter off the precipitate. 4. Reduce the filtrate volume under vacuum to ca. 10-20 ml and a lot of nice yellow needle-like crystals appear. 5. Filter and keep the crystals, and let the crystals dry in air. 6. Use diluted HCl to recrystallize and obtain the pure product (herein after compound JP0916). Note: All containers must be clean and rinsed with deionized water before use. All steps should be conducted under yellow light as much as possible.

Reference： [1]Patent: US2010/152154,2010,A1 .Location in patent: Page/Page column 2

46
[ 15663-27-1 ]
[ 5550-12-9 ]
[Pt(NH₃)2(guanosine-5'-monophosphate)2]^(2-) [ No CAS ]
[Pt(NH₃)2Cl(guanosine-5'-monophosphate)]^(1-) [ No CAS ]

Reference： [1]European Journal of Inorganic Chemistry,2010,p. 5439 - 5445

47
[ 1122-61-8 ]
[ 15663-27-1 ]
[ 1402912-55-3 ]

Reference： [1]Chemistry - A European Journal,2012,vol. 18,p. 10630 - 10642,13

48
[ 15663-27-1 ]
[ 7631-99-4 ]
[ 16490-02-1 ]
C₆H₁₄N₆O₄Pt₂⁽²⁺⁾*2NO₃^(1-)*0.5H₂O [ No CAS ]

Reference： [1]Zeitschrift fur Anorganische und Allgemeine Chemie,2012,vol. 638,p. 1691 - 1698,8

49
[ 15663-27-1 ]
[ 7631-99-4 ]
[ 122-05-4 ]
C₆H₁₄N₆O₄Pt₂⁽²⁺⁾*2NO₃^(1-)*3H₂O [ No CAS ]

Reference： [1]Zeitschrift fur Anorganische und Allgemeine Chemie,2012,vol. 638,p. 1691 - 1698,8

50
[ 15663-27-1 ]
[ 67603-23-0 ]
[ 1412458-66-2 ]

Yield	Reaction Conditions	Operation in experiment
38%	With barium hydroxide octahydrate; silver sulfate; In methanol; water; at 20℃; for 78h;	<strong>[15663-27-1]cisplatin</strong> (600 mg) were suspended in 25 mL water and 624 mg Ag2SO4 were added with stirring. After being stirred at room temperature for 24 h, the precipitates were removed by filtration. The obtained filtrate was mixed with a methanolic solution (20 mL) containing 375 mg HNPAC. Then, an aqueous solution prepared by dissolving 599 mg Ba(OH)2·8H2O in 20 mL water was added dropwise into the mixture in 6 h with stirring. After stirring in dark at room temperature for 48 h, the precipitate was removed by filtration and 50 mL methanol was added. Then, the solvents were removed in vacuo and the residue was washed by methanol and acetone in sequence. NMPt (310 mg) was obtained as pale yellow powders with a yield of 38%.

Reference： [1]Inorganica Chimica Acta,2012,vol. 393,p. 198 - 203

51
[ 15663-27-1 ]
[ 229-87-8 ]
phenanthriplatin [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
59.4%		To a solution of <strong>[15663-27-1]cisplatin</strong> (0.30 g, 10 mmol) in 15 mL DMF was added AgN03 (0.169 g, 1 equiv) and the reaction was stirred under protection from light at 60 C. After 16 h, a AgCl precipitate was filtered. To the supernatant, phenanthridine (0.161 g, 0.9 equiv) was added, and the reaction was stirred for 16 h at 60 60 C. The reaction mixture was evaporated under reduced pressure, and the residue was dissolved in 30 mL of MeOH. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was stirred vigorously and diethylether (100 mL) was then added to precipitate the desired compound as a solid. The diethylether and methanol were decanted and washed 2 times with 50 mL of diethylether. The compound was purified by redissolving it in methanol and precipitating it by adding the methanol solution dropwise to vigorously stirred diethyl ether. The final compound was isolated by vacuum filtration and dried in vacuo. X-ray quality crystals were obtained from methanol/diethylether. White solid. Yield: 59.4% (0.30 g). ESI-MS m/z calculated (M+): 443.06, found: 443.1. 1H NMR (DMSO-d6): delta 4.43 (3H, broad), 4.60 (3H, broad), 7.93 (2H, q), 8.02 (1H, t), 8.14 (1H, t), 8.46 (1H, d), 8.93 (2H, q), 9.78 (1H, d), 9.95 (1H, s). 13C NMR (DMSO-d6): delta 122.53, 123.27, 125.23, 126.20, 129.02, 129.36, 130.17, 131.72, 134.24, 142.39, 160.14. 195Pt NMR (DMSO-d6): delta -2298.51. Anal. Calcd. for Ci3H15ClN403Pt: C, 30.87; H, 2.99; N, 11.08; Found: C, 31.08; H, 3.02; N, 11.03.

Reference： [1]Patent: WO2012/177931,2012,A1 .Location in patent: Page/Page column 50-51

52
cis-diaminediiodoplatinum(II) [ No CAS ]
potassium chloride [ No CAS ]
[ 15663-27-1 ]

Yield	Reaction Conditions	Operation in experiment
60%		The complex cis-[PtI2(NH3)2] (0.82 mmol, 400 mg) was dissolved in 50 mL of distilled water at 80 C and 2 molar equiv. of AgNO3(280 mg) was added. After 20 min of stirring of the reaction mixture in the dark (under aluminiumfoil), the formed precipitate was filtered off and the obtained filtrate was concentrated to the volume of ca. 5 mL. Anexcess of KCl (13.3 mmol, 990 mg) was added to the concentrated solution at 0 C, leading to the immediate precipitation of the yellow solid of cis-[PtCl2(NH3)2] (cisplatin),which was collected after 15 min of stirring at 0 C. Theproduct was washed by EtOH (3 mL) and DEE (2 × 3 mL),and dried under vacuum (1 h). The yield was ca. 60% (calculatedto cis-[PtI2(NH3)2]).

Reference： [1]Applied Organometallic Chemistry,2019,vol. 33
[2]Journal of Biological Inorganic Chemistry,2019,vol. 24,p. 257 - 269
[3]Dalton Transactions,2013,vol. 42,p. 3482 - 3489
[4]Inorganic Chemistry,2017,vol. 56,p. 10474 - 10480

53
[ 15663-27-1 ]
hydroxo aluminum octacarboxy phthalocyanine sodium salt [ No CAS ]
hydroxo aluminium tris(diammine platinum) octacarboxy phthalocyanine sodium salt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
87%		An aqueous solution of cis-diamminedichloro platinum (0.055 g, 0.19 mmol) and silver nitrate (0.047 g, 0.28 mmol) in 10 mL deionised water was stirred in the dark for 24 h. As soon as the two salts were added together, the precipitation of silver chloride occurred. The precipitate was however filtered after 24 h of reaction. The filtrate was collected and mixed with a solution of the sodium salt of Al(OH)OCPc (0.052 g, 0.045 mmol). The ratio of Al(OH)OCPc to the Pt complex was 1:3. The solution was stirred for 4 h at 55 C, following literature methods [2,3]. The solution was allowed to stand for 12 h and the precipitate was collected. The conjugate was washed with water, ethanol, acetone and diethyl ether. Yield 0.063 g (87%). IR (KBr, cm-1): 3436 (OH), 3125 (NH), 1712 (C=O), 1699, 1560 1437, 1347. UV-Vis (PBS): lambdamax log epsilon: 359 (4.22), 630 nm (4.65), 699 (5.23) nm. 1H NMR (D2O): delta = 8.6 (8H, broad, Ar-H), delta = 2.7 (18H, broad, NH3). Calc. for Na2C40H27N14O17AlPt3: C, 29.71; N, 12.00; H, 2.41. Found: C, 30.32; N, 11.57; H, 3.56%.

Reference： [1]Polyhedron,2013,vol. 55,p. 121 - 125

54
[ 15663-27-1 ]
[ 7732-18-5 ]
[ 68-04-2 ]
C₆H₁₂N₂O₇Pt [ No CAS ]
C₆H₁₄N₂O₈Pt [ No CAS ]
[ 77-92-9 ]

Reference： [1]Chemical Communications,2013,vol. 49,p. 9482 - 9484

55
[ 15663-27-1 ]
succinylacetone [ No CAS ]
silver nitrate [ No CAS ]
[Pt(succinylacetonate-H)(NH₃)₂](NO₃) [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
28%		Cisplatin (500mg, 1.67mmol) and AgNO3 (552mg, 3.25mmol) were stirred in 10ml H2O in the absence of light at room temperature for 16hr. The resulting mixture was filtered to remove AgCl. To the filtrate, a solution of NaOH (67mg, 1.68mmol) and succinylacetone (269mg, 1.70mmol) in 5ml of H2O was added dropwise. After stirring at room temperature (RT) for 5hr, the resulting solution was concentrated to dryness at 60C under reduced pressure to afford an orange oil. This oil was dissolved in 3ml of H2O and acidified with three drops of 25% HNO3. Acetone (50ml) was added, and the resulting turbidwhite suspension was stirred for ?3min, resulting in the deposition of an oily orange-brown residue. The turbid supernatant was decanted and mixed with 50ml of a 1:1 (v/v) mixture of acetone and diethyl ether. Upon stirring at RT for ?5min, an orange-brown residue deposited again. The cloudy supernatant was decanted and poured directly into 150ml of diethyl ether. The mixture was stored at -40C for 1.5hr and filtered to collect a whitesolid. The white solid was washed with 2× 10ml diethyl ether and then dried in vacuo. The yield equals 203mg (28%). Characterization data are given in Note S1A.

Reference： [1]Chemistry and Biology,2013,vol. 20,p. 1323 - 1328

56
[ 15663-27-1 ]
[ 605-03-8 ]
[ 1579286-49-9 ]

Yield	Reaction Conditions	Operation in experiment
60%		To a solution of cisplatin (0.15 g, 0.5 mmol) in DMF (5 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgC1 precipitate was removed by filtration. <strong>[605-03-8]<strong>[605-03-8]4-phenylquinol</strong>ine</strong> (0.1 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 30 mL methanol. Unreacted yellow cisplatin was removed by filtration.The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HCl) to afford compound 4 as a white solid (120 mg, 60% yield). 1H NMR (500 MHz, DMSO): delta 9.72 (d, J = 8.0 Hz, 1H), 9.30 (d, J = 6.0 Hz, 1H), 8.09 (t, J = 8.0 Hz, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.80 (t, J = 8.0 Hz, 1H), 7.65-7.5 8 (m, 6H), 4.60 (s, 3H), 4.44 (s, 3H). LC-MS m/z: 468 (M+).

Reference： [1]Patent: WO2014/43243,2014,A2 .Location in patent: Paragraph 00230

57
[ 5332-25-2 ]
[ 15663-27-1 ]
[ 1579286-51-3 ]

Yield	Reaction Conditions	Operation in experiment
60%		To a solution of <strong>[15663-27-1]cisplatin</strong> (0.15 g, 0.5 mmol) in DMF (5 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgC1 precipitate was removed by filtration. 6-Bromoquinoline (0.1 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 30 mL methanol. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HC1) to afford compound 5 as a white solid (150 mg, 60% yield). 1H NMR (500 MHz, DMSO): delta 9.49 (d, J = 8.5 Hz, 1H), 9.32 (d, J = 5.0 Hz, 1H), 8.64 (d, J = 8.5 Hz, 1H), 8.49 (d, J = 2.0 Hz, 1H), 8.21 (dd, J = 8.5 Hz,2.0 Hz, 1H), 7.74 (dd, J = 8.5 Hz, 5.0 Hz, 1H), 7.59-7.56 (m, 2H), 7.50-7.49 (m, 1H), 4.68 (s, 3H),4.51 (s, 3H). LC-MS m/z: 471 (M+).

Reference： [1]Patent: WO2014/43243,2014,A2 .Location in patent: Paragraph 00231

58
[ 15663-27-1 ]
[ 612-95-3 ]
[ 1579286-53-5 ]

Yield	Reaction Conditions	Operation in experiment
60%		To a solution of <strong>[15663-27-1]cisplatin</strong> (0.15 g, 0.5 mmol) in DMF (5 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgC1 precipitate was removed by filtration. 6-phenylquinoline (0.1 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 30 mL methanol. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HCl) to afford compound 6 as a white solid (150 mg, 60% yield). 1H NMR (500 MHz, DMSO): delta 9.62 (d, J = 8.5 Hz, 1H), 9.26 (d,J 5.0 Hz, 1H), 8.71 (d,J 8.5 Hz, 1H), 8.46 (d,J 1.5 Hz, 1H), 8.39 (dd,J= 8.5 Hz,1.5 Hz, 1H), 7.89 (d, J = 8.5 Hz, 2H), 7.71 (dd, J = 8.5 Hz, 5.0 Hz, 1H), 7.59-7.56 (m, 2H),7.50-7.49 (m, 1H), 4.70 (s, 3H),4.50 (s, 3H). LC-MS m/z: 469 (M+)

Reference： [1]Patent: WO2014/43243,2014,A2 .Location in patent: Paragraph 00233

59
[ 15663-27-1 ]
[ 62833-92-5 ]
[ 1579284-48-2 ]

Yield	Reaction Conditions	Operation in experiment
45%		To a solution of <strong>[15663-27-1]cisplatin</strong> (0.15 g, 0.5 mmol) in DMF (5 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgCl precipitate was removed by filtration. 7,8,9,10- tetrahydrophenanthridine (0.091 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 20 mL methanol. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HCl) to afford compound 7 as a white solid (110 mg, 45% yield). 1H NMR (500 MHz, DMSO): delta 9.53 (d, J = 8.0 Hz, 1H), 9.04 (s, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.92 (t, J = 8.0 Hz, 1H), 7.75 (t, J= 8.0 Hz, 1H), 4.64 (s, 3H), 4.44 (s, 3H), 3.23-3.14 (m, 2H), 2.99-2.87 (m, 2H), 1.93-1.85 (m, 4H). LC-MS m/z: 447 (M+).

Reference： [1]Patent: WO2014/43243,2014,A2 .Location in patent: Paragraph 00236

60
[ 15663-27-1 ]
[ 90679-75-7 ]
[ 1579284-61-9 ]

Yield	Reaction Conditions	Operation in experiment
56%		To a solution of <strong>[15663-27-1]cisplatin</strong> (0.15 g, 0.5 mmol) in DMF (5 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgCl precipitate was removed by filtration. 1,2,3,4-Tetrahydrophenanthridine (0.091 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 20 mL methanol. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HCl) to afford compound 8 as a white solid (140 mg, 56% yield). 1H NMR (500 MHz, DMSO): delta 9.62 (s, 1H), 8.25 (d, J = 8.0 Hz, 1H), 8.08 (d, J = 8.0 Hz, 1H), 7.94 (t, J = 8.0 Hz, 1H), 7.77 (t, J = 8.0 Hz, 1H), 4.64 (s, 3H), 4.37 (s, 3H), 3.81-3.70 (m, 2H), 3.13-3.08 (m, 2H), 1.96-1.85 (m, 4H). LC-MS m/z: 447 (M+).

Reference： [1]Patent: WO2014/43243,2014,A2 .Location in patent: Paragraph 00237

61
[ 5332-24-1 ]
[ 15663-27-1 ]
[ 1579286-45-5 ]

Yield	Reaction Conditions	Operation in experiment
60%		To a solution of <strong>[15663-27-1]cisplatin</strong> (0.15 g, 0.5 mmol) in DMF (15 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgC1 precipitate was removed by filtration. 3-bromoquinoline (0.1 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction was concentrated under reduced pressure, and the resulting residue was dissolved in 30 mL methanol. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HCl) to afford compound 2 as a white solid (150 mg, 60% yield). 1H NMR (500 MHz, DMSO): delta 9.53 (d, J = 8.5 Hz, 1H), 9.42 (d, J = 2.0 Hz, 1H), 9.09 (s, 1H), 8.12-8.07 (m, 2H), 7.86 (d, J = 8.5 Hz, 1H), 4.56 (s, 3H),4.47 (s, 3H). LC-MS m/z: 472 (M+).

Reference： [1]Patent: WO2014/43243,2014,A2 .Location in patent: Paragraph 00226

62
[ 254-60-4 ]
[ 15663-27-1 ]
silver nitrate [ No CAS ]
[ 1628306-60-4 ]

Reference： [1]ChemMedChem,2014,vol. 9,p. 1161 - 1168

63
[ 15663-27-1 ]
[ 27148-03-4 ]
cis-[Pt(II)(thiosaccharinate)₂(NH₃)₂] [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
89%	In water; for 2h;Reflux;	a solution of thiosaccharinate (0.26 g, 1.33 mmol) in hot water (30 cm3) was added to a solution of cis-[PtCl2(NH3)2] (0.20 g, 0.667 mmol) in hot water (15 cm3). The mixture was reuxed for 2 h. The light-brown solid formed was ltered off washed several times with distilled water and dried in vacuo. Yield: 89% (0.39 g). Anal. Calcd. for C14H14N4O4PtS4: C, 26.88; H, 2.26; N,8.96. Found: C, 26.33; H, 2.09; N, 8.86%. IR (KBr) (nu, cm-1): 3471 m, 3413 m, 3286 m, 1627s,1440w, 1373s, 1315s, 1236 m, 1155 m, 1126s, 1008w, 817 s, 515 m. 1H NMR (d6-DMSO): 7.96-7.90 (m, 4H), 7.82-7.75 (m, 4H), 4.54 (s, 6 H). 13C{1H} NMR (d6-DMSO): 182.8, 137.6,133.7, 133.4, 133.1, 124.3, 120.7 ppm.

Reference： [1]Journal of Inorganic Biochemistry,2014,vol. 141,p. 55 - 57

64
[ 15663-27-1 ]
[ 822-16-2 ]
cis-diamine Pt(II) chloride monostearic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
6.08%		The cisplatin intermediate was prepared as follows. Cis-dichlorodiamine Pt (II) (240 mg, 0.8 mmoles) (Sigma) was suspended in 30 ml distilled water and heated to 70 C to dissolve the complex. The solution was then cooled to RT. Thereafter, aqueous solution of silver nitrate ((135.9 mg, 0.8 mmoles) in 10 ml of water) was added drop-wise to the solution of starting material under stirring (400 rpm). The formation of translucent white precipitate of silver chloride was commenced immediately after the addition of the aqueous solution. The mixed solution was stirred for 3 hr at RT under light shielding conditions. The resulting precipitate of silver chloride was filtered off (Corning polystyrene Filter System, Corning) (0.22 tM) and washed with water. The combined filtrate was used in the following step without further treatment.[0098] The Pt (II) monostearate complex was prepared as follows. To an aqueous solution of <strong>[822-16-2]sodium stearate</strong> ((245.15 mg, 0.8 mmoles) (Sigma) in 10 ml of water) was added the aqueous solution obtained above and stuffed at RT for 3 weeks under light shielding conditions to complete the reaction. The translucent white precipitate formed was filtered off, washed with a small amount of ether, and dried in vacuum desiccator to obtain the crude product. [0099] Because the crude product contained a mixture of mono- and di-fatty acid platinum derivatives, and the mono-fatty acid platinum derivative was soluble in chloroform, chloroform was used to purify the mixture. The crude product was suspended in 25 ml chloroform in conical tube, vortex mixed for 5 mm, and kept at RT for 24 hr. Tubes were then centrifuged (5000 rpm, 10 mm) (Beckman Coulter, Inc.), and the supernatant was carefully transferred into glass vials and vacuum dried to obtain the Pt-MSA complex (yield = 6.08%).

Reference： [1]Patent: WO2015/13565,2015,A1 .Location in patent: Paragraph 0097 - 0099

65
[ 15663-27-1 ]
[ 822-16-2 ]
cis-diamine Pt (II) chloride monostearic acid [ No CAS ]
cis-diamine Pt (II) distearic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
6.08%		The cisplatin intermediate was prepared as follows. Cis-dichlorodiamine Pt (II) (240 mg, 0.8 mmoles) (Sigma) was suspended in 30 ml distilled water and heated to 70 C to dissolve the complex. The solution was then cooled to RT. Thereafter, aqueous solution of silver nitrate ((135.9 mg, 0.8 mmoles) in 10 ml of water) was added drop-wise to the solution of starting material under stirring (400 rpm). The formation of translucent white precipitate of silver chloride was commenced immediately after the addition of the aqueous solution. The mixed solution was stirred for 3 hr at RT under light- shielding conditions. The resulting precipitate of silver chloride was filtered off (Corning polystyrene Filter System, Corning, Amsterdam, Netherlands) (0.22 muMu) and washed with water. The combined filtrate was used in the following step without further treatment. [00193] The Pt (II) monostearate complex was prepared as follows. To an aqueous solution of <strong>[822-16-2]sodium stearate</strong> ((245.15 mg, 0.8 mmoles) (Sigma) in 10 ml of water) was added the aqueous solution obtained above and stirred at RT for 3 wk under light- shielding conditions to complete the reaction. The translucent white precipitate formed was filtered off, washed with a small amount of ether, and dried in vacuum desiccator to obtain the crude product. [00194] Because the crude product contained a mixture of mono- and di-fatty acid Pt derivatives, and the mono-fatty acid Pt derivative was soluble in chloroform, chloroform was used to purify the mixture. The crude product was suspended in 25 ml chloroform in conical tube, vortex mixed for 5 min, and kept at RT for 24 hr. Tubes were then centrifuged (5000 rpm, 10 min) (Beckman-Coulter, Inc.), and the supernatant was carefully transferred into glass vials and vacuum dried to obtain the Pt (II) monostearic acid complex (yield = 6.08%).

Reference： [1]Patent: WO2015/13566,2015,A1 .Location in patent: Paragraph 00192 - 00194

66
[ 15663-27-1 ]
[ 125074-46-6 ]

Yield	Reaction Conditions	Operation in experiment
75%	With dihydrogen peroxide; In water; at 70℃; for 5h;	Accurately weigh <strong>[15663-27-1]cisplatin</strong> (1.00 g, 3.30 mmol) in a 25 mL round bottom flask, stir into 2 mL of distilled water, and slowly add H2O2 (30% w/v, 10.0 mL) dropwise at 70 C for 5 hours. After completion of the reaction, the reaction solution was cooled to room temperature and then placed at 4 C overnight, then the supernatant was removed by centrifugation to give a pale yellow solid. The solid were washed twice with distilled water, ethanol and ether, and then dried in vacuo to give a pale yellow solid 826.65mg, 75% yield.
	With dihydrogen peroxide; In water; at 20 - 65℃;	Dissolve <strong>[15663-27-1]cisplatin</strong> (2.0 mmol, 600.0 mg) in 35.0 mL of deionized water, add 12.0 mL of 30% hydrogen peroxide (H 2 O 2 ) under magnetic stirring, perform redox reaction at 65 C for 5 h, and then react at room temperature overnight. Filtration of H2O2 to obtain a pale yellow solid, which is cis-diamine dichlorodichloroplatinum (IV);
	With dihydrogen peroxide; In water; at 20 - 50℃; for 25h;	(1) Ultrasonic disperse 100 mg of <strong>[15663-27-1]cisplatin</strong> (CDDP) in 5 mL of 30% volume H2O2 aqueous solution, react at 50 C for 1 h, then stand for 24 h, then centrifuge and vacuum dry to obtain hydroxylated <strong>[15663-27-1]cisplatin</strong> Compound (CDDP-OH)

Reference： [1]Journal of the American Chemical Society,2015,vol. 137,p. 8324 - 8327
[2]Patent: CN109438522,2019,A .Location in patent: Paragraph 0096; 0104; 0105; 0106; 0107; 0108; 0109
[3]Chemical Communications,2015,vol. 51,p. 1807 - 1810
[4]Patent: CN110128483,2019,A .Location in patent: Paragraph 0061; 0063
[5]Patent: CN110898229,2020,A .Location in patent: Paragraph 0015

67
[ 15663-27-1 ]
[ 7722-84-1 ]
[ 125074-46-6 ]

Yield	Reaction Conditions	Operation in experiment
93.3%	at 70℃; for 5h;Darkness;	The specific synthesis steps are:Weigh 1.2 g of <strong>[15663-27-1]cisplatin</strong> (4.00 mmol) into a 100 mL round bottom flask, add 60 mL of 30% hydrogen peroxide solution, and stir vigorously at 70 C for 5 h in the dark.As the reaction progresses, <strong>[15663-27-1]cisplatin</strong> slowly dissolves,Finally, a transparent yellow solution is formed.After the reaction was completed, a small amount of insoluble material was removed by filtration while hot. After cooling at room temperature, it was left at 4 C overnight to obtain a crystalline precipitate of platinum oxide. Product centrifugation,It was washed once with deionized water and dried under vacuum overnight to obtain a light yellow powder.Yield: 1.26g (93.3%).
90%	at 4 - 75℃; for 7h;Darkness;	Add CDDP (1 g, 3.33 mmol) to a 100 mL round bottom flaskAnd 15 ml of 30% hydrogen peroxide (30%, w/v).Stir in the dark at 75 C for 5 hours.Cool at 4 C for 2 hours,Light yellow crystals were obtained by filtration under reduced pressure.Use water separately,Wash with ethanol and ether,After drying, product II (998 mg, yield 90%) was obtained.
85%	In water; for 5h;	This compound was prepared following previously reportedmethods [40]. Hydrogen peroxide (30 wt%, 2.5 mL) was added dropwise to a round bottom flask containing <strong>[15663-27-1]cisplatin</strong> (300 mg,1 mmol).The reaction mixture was heated to 75 C for 5 h. The bright yellowsolutionwas kept at 4 C to afford yellow crystals. The crystals wererecovered by filtration and washed with cold water, ethanol andether. Finally, the product was dried in vacuum. Yield 85% (283 mg,0.85 mmol). Melting Point: 291e294 C. IR (KBr): 3461 (s, OHstretch), 1075 (m, PteOH bend), 539 (m, PteN(O) stretch).Elemental analysis (%): calcd for Cl2H8N2O2Pt: H, 2.41; N, 8.39.Found: H, 2.45; N, 8.53. ESI-HRMS m/z calcd for Cl2H9N2O2Pt: [M H] 333.9611, found 334.2917.

85%	at 75℃; for 5h;	Hydrogen peroxide (30 wt%, 2.5 mL) was added dropwise to around bottom flask containing <strong>[15663-27-1]cisplatin</strong> (300 mg, 1 mmol). The reaction mixture was heated to 75 C for 5 h. The bright yellow solution was kept at 4 C in the dark to afford yellow crystals. The crystals were recovered by filtration and was washed with cold water, ethanol and ether, and dried in vacuum. Yield 85% (283 mg,0.85 mmol). IR (KBr): 3461(s, OH stretch), 1075 (m, PteOH bend),539 (m, PteN(O) stretch). Melting Point: 291-294 C. Elementalanalysis (%): calcd for Cl2H8N2O2Pt: H, 2.41; N, 8.39. Found: H, 2.45;N, 8.53. HR-MS m/z calcd for Cl2H9N2O2Pt: [M + H]+, 333.9611;found, 334.2917.
75%	In water; at 60℃; for 4h;	To a 250 mL round-bottom flask, 1.0 g of <strong>[15663-27-1]cisplatin</strong> 6-1, 30 mL of distilled water were added, and stirred to disperse, and 50 mL of hydrogen peroxide with a concentration of 30% was slowly added dropwise to the reaction system, and the temperature was raised to 60 C. to stir for 4 h. The reaction was stopped, and the crystal was left at 4 C for 12 hours. The yellow solid was separated by filtration, added to an appropriate amount of distilled water, heated to 80 C to dissolve it, and crystallized at 4 C for 12 hours. 75%).
74%	In water; at 60℃; for 4h;	To a 250 mL round-bottomed flask, 1.0 g of <strong>[15663-27-1]cisplatin</strong> and 30 mL of distilled water were stirred and dispersed. 50 mL of 30% hydrogen peroxide was slowly added dropwise to the reaction system, and the temperature was raised to 60 C. and the reaction was stirred for 4 h. Stop the reaction, leave it to crystallize at -4 C for 12 hours, filter to obtain a yellow solid, add an appropriate amount of distilled water, heat to 80 C to dissolve, and crystallize at 4 C for 12 hours. Filter to obtain compound 4a-1 yellow crystals (0.82g , 74%).
67.2%	In water; at 20℃; for 144h;	(0277) 150 g of <strong>[15663-27-1]cisplatin</strong> is suspended in about 300 ml of water in a 2 liter three-necked flask (provided with precision glass stirrer) and added with 350 ml H202 (35%) in portions with stirring over a period of 2 days. Stirring is continued for another 4 days at about 20C. Thereafter, the raw product is sucked off, washed with a small amount of ice water, dissolved in a precisely sufficient amount of 0,5 N sulphuric acid, and subsequently precipitated with 35% NaOH (pH7-8). After storage in a refrigerator overnight, the yellow crystalline mass is sucked off, washed with a small amount of cold water, ethanol and eventually with ether and dried in vacuum. Yield (3 batches): 336.7g (67.2% of theoretical).
43%	In water; at 75℃; for 5h;	H2O2 (60 mL, 30% w/v) was added to cis-diamminedichloroplatinum(II) (1 g,3.3 mmol). The mixture was stirred for 5 h at 75 C. The resulting yellow solutionwas kept overnight to crystallize. The precipitate was filtered and washed with coldwater, ethanol and diethyl ether, then dried in vacuum. N-H), 1361, 1039 (s, Pt-O), 902 (s, Pt-Cl), 554 (s, Pt-N).
	at 20℃; for 8h;	Cisplatin (600mg, 2mmol) placed in a flask, and then 30% hydrogen peroxide was added 10mL, After stirring at room temperature for 8 h, filtered to remove the hydrogen peroxide to give Cisplatin (IV) - (OH)2 Yellow powder.
	at 60℃;	cis-[Pt(NH3)2Cl2(OH)2]was synthesized by treating cis-[Pt(NH3)2Cl2] with a 10% H2O2 solution at 60C [12].
	In water; at 65 - 75℃;Darkness;	Preparation of an axially bishydroxy-coordinated tetravalent platinum compound (oxoplatin),Specific steps are as follows:200mg of divalent <strong>[15663-27-1]cisplatin</strong> (CDDP),6 mL of deionized water and 6.5 mL of 30% hydrogen peroxide were added to the 50 mL reaction flask.Reacting at 65-75 C (preferably 70 C) for 10-12 h in the dark,After concentrating by steaming,The ice water is cooled and the product is obtained.Using ice water in turn,Ethanol,The reaction product was washed with diethyl ether and dried under vacuum.An axially bishydroxy-coordinated tetravalent platinum compound Pt(IV)-(OH)2 (oxoplatin) was obtained.

Reference： [1]Patent: CN110981918,2020,A .Location in patent: Paragraph 0042-0046
[2]RSC Advances,2015,vol. 5,p. 81668 - 81681
[3]Patent: CN109021026,2018,A .Location in patent: Paragraph 0044; 0060; 0061
[4]European Journal of Medicinal Chemistry,2018,vol. 157,p. 1292 - 1299
[5]European Journal of Medicinal Chemistry,2019,vol. 167,p. 377 - 387
[6]International Journal of Nanomedicine,2017,vol. 12,p. 3697 - 3710
[7]Chemical Communications,2018,vol. 54,p. 5369 - 5372
[8]Patent: CN111072725,2020,A .Location in patent: Paragraph 0090-0093
[9]Patent: CN110423254,2019,A .Location in patent: Paragraph 0043-0045
[10]Inorganic Chemistry,2019,vol. 58,p. 6507 - 6516
[11]Patent: WO2020/2056,2020,A1 .Location in patent: Page/Page column 24
[12]Research on Chemical Intermediates,2019,vol. 45,p. 3155 - 3164
[13]RSC Advances,2015,vol. 5,p. 43391 - 43401
[14]New Journal of Chemistry,2015,vol. 39,p. 9234 - 9241
[15]Journal of Materials Chemistry B,2016,vol. 4,p. 2114 - 2123
[16]Patent: CN105753922,2016,A .Location in patent: Paragraph 0060; 0061; 0062
[17]Patent: CN103588818,2016,B .Location in patent: Paragraph 0060; 0061
[18]Journal of Medicinal Chemistry,2017,vol. 60,p. 5736 - 5748
[19]Russian Journal of Inorganic Chemistry,2018,vol. 63,p. 923 - 929
Zh. Neorg. Khim.,2018,vol. 63,p. 880 - 887,8
[20]Patent: CN108144067,2018,A .Location in patent: Paragraph 0068; 0069
[21]Bioorganic Chemistry,2020,vol. 99

68
[ 15663-27-1 ]
[ 2156-56-1 ]
[ 1421629-47-1 ]

Yield	Reaction Conditions	Operation in experiment
87%		In brief, cisplatin (0.30 g, 1 mmol), HNO3 (100 mul), andsilver nitrate (0.34 g, 2 mmol) were added into a roundbottomflask containing 50 ml pure water. The reactionmixture was stirred in the dark at room temperature for48 h. The resultant turbid solution was filtered to removewhite silver chloride. To the yellow colored solution,<strong>[2156-56-1]sodium dichloroacetate</strong> (0.36 g, 2.4 mmol) was added toform a precipitate of DCA-Pt(II). The solid was filtered and dried under vacuum. A weight of 0.42 g of the productwas obtained in an 87% yield.

Reference： [1]Anti-Cancer Drugs,2015,vol. 26,p. 698 - 705

69
[ 15663-27-1 ]
[ 60-00-4 ]
C₁₀H₂₄N₆O₈Pt₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide; In water; at 20℃; for 60h;	To the reaction flask 33.69mg <strong>[60-00-4]EDTA</strong> and 70mL water, with 0.1M Of NaOH to adjust pH to 6.8, adding 69.18mg of CDDP. The reaction was stirred 60h at room temperature After using a 500 MWCO dialysis 30h is dialysis bag, liquid is collected, and lyophilized to give Pale yellow crystalline solid, <strong>[60-00-4]EDTA</strong> binuclear platinum complexes.

Reference： [1]Patent: CN103467529,2016,B .Location in patent: Paragraph 0036-0037

70
[ 15663-27-1 ]
[ 64-02-8 ]
C₁₀H₂₄N₆O₈Pt₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide; In water; at 20℃; for 60.0h;pH 8.2;	To the reaction flask was added 32.73mg dihydrate disodium edetate and 55mL of pure Water, pH adjusted with 0.1M NaOH to 8.2, was added 52.77mg of CDDP. Room temperature After stirring 70h of reaction, with a 500 MWCO dialysis 30h is dialysis bag, liquid is collected, Freeze drying light yellow crystalline solid, EDTA binuclear platinum complexes.

Reference： [1]Patent: CN103467529,2016,B .Location in patent: Paragraph 0072-0073

71
[ 15663-27-1 ]
C₂₂H₁₆N₂O₂ [ No CAS ]
C₂₂H₁₆Cl₂N₂O₂Pt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
59.8%	With ethylenediamine; In methanol; water; at 20℃; for 6h;	General procedure: One millimole of ethylenediamine solution was dropped to solution of 1 mmol H2L1 in absolute methyl alcohol (30 mL) to make H2L1 completely dissolved, and then 1 mmol Potassium platinochloride in 3 mL water was dropwise to the resulting solution. Leave the reaction stirring at room temperature for 6 h. The crude product of Pt(II) metal complex C1 was obtained and washed by distilled water, ethanol for three times respectively.

Reference： [1]BioMetals,2017,vol. 30,p. 17 - 26

72
[ 15663-27-1 ]
[ 69839-83-4 ]
C₇H₁₈ClN₅O₄Pt₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		300 mg of cisplatin and 169.87 mg of silver nitrate were dissolved in 10 mL of DMF, 24 hours after the reaction to remove silver chloride precipitation, the supernatant for the solution one; 42.3 mg of 3,4-dihydroxybenzenamic acid was mixed with 35.3 mg of sodium carbonate in 5 mL of DMF, After the reaction to remove the insoluble material, the supernatant for the solution two; solution 1 and solution two mixed reaction 48h, Removing the organic solvent, dissolving with methanol to remove excess cisplatin, and recrystallizing to obtain an amphiphilic drug-drug complex,Its structure (c) is as follows;

Reference： [1]Patent: CN106860872,2017,A .Location in patent: Paragraph 0042; 0043; 0044

73
[ 15663-27-1 ]
[ 1069-66-5 ]
C₁₆H₃₆N₂O₄Pt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		300 mg of cisplatin and 169.87 mg of silver nitrate were dissolved in 20 mL of water and the silver chloride precipitate was removed after 24 h, Supernatant for the solution three; After adding 332 mg of <strong>[1069-66-5]sodium valproate</strong> to solution three for 48 h,Removal of water, in ether precipitation in the amphiphilic drug - drug complex, the structural formula (d) is as follows:

Reference： [1]Patent: CN106860872,2017,A .Location in patent: Paragraph 0046; 0047; 0048

74
[ 15663-27-1 ]
[ 149647-78-9 ]
C₁₄H₃₁ClN₆O₃Pt₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		cisplatin and 169.87mg 300mg silver nitrate dissolved in 10mL DMF and the reaction is removed after precipitation of silver chloride 24h, a solution to obtain a supernatant; and 88.1mg 13.3mg <strong>[149647-78-9]vorinostat</strong> with a sodium hydroxide dispersion in 5mL of methanol, insolubles were removed after the reaction to give a supernatant solution II; a solution and mixing two reaction solution 48h, the organic solvent is removed, dissolved in methanol to remove excess cisplatin, recrystallized amphiphilic drugs - drug complexes having the formula (a) below

Reference： [1]Patent: CN106860872,2017,A .Location in patent: Paragraph 0033; 0034; 0035

75
[ 15663-27-1 ]
[ 89-57-6 ]
C₇H₁₁N₃O₃Pt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
60%	With sodium carbonate; silver nitrate; In N,N-dimethyl-formamide; at 20℃; for 24h;Darkness;	150 mg of <strong>[15663-27-1]cisplatin</strong>), AgNO3 (170 mg), Mesalazine (76.6 mg) and Na2C03 (35.3 mg) were added into a round-bottom flask followed by addition of 10 ml of DMF and stirring at room temperature for 24 h. The AgCl precipitate was discarded by filtration, Concentrated by centrifugation, added with 50 ml of ethyl acetate, and then washed three times with 50 ml of 0.1 M Na2CO3 and washed with water three times. The ethyl acetate layer was collected and dried over anhydrous sodium sulfate overnight. Filtration, the filtrate with methanol: chloroform = 1: 9 eluent, silica gel column chromatography to obtain <strong>[15663-27-1]cisplatin</strong> - Mesalazine complex, the yield of 60%, the structural formula shown in Figure 50.

Reference： [1]Patent: CN107296794,2017,A .Location in patent: Paragraph 0182-0184

76
[ 15663-27-1 ]
[ 13710-19-5 ]
C₁₄H₁₆ClN₃O₂Pt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
60%	With sodium carbonate; silver nitrate; In N,N-dimethyl-formamide; at 20℃; for 24h;Darkness;	isplatin (I50 mg), AgNO3 (170 mg), tolfenamic acid (131 mg) and Na2C03 (35.3 mg)Add a round bottom flask, Then 10 ml of DMF was added and stirred for 24 h at room temperature in the dark.AgCl precipitate was discarded by centrifugation, the filtrate was concentrated after adding 50ml of ethyl acetate, and then washed with 50ml 0.1M Na2C03 three times, washed three times,The ethyl acetate layer was collected and dried over anhydrous sodium sulfate overnight.Filtration, the filtrate with methanol: chloroform = 1: 9 eluent,The compound of cisplatin-tolfenamic acid was isolated by silica gel column chromatography with a yield of 60%. The structural formula is as shown in formula 1

Reference： [1]Patent: CN107296794,2017,A .Location in patent: Paragraph 0030-0032; 0036-0037

77
[ 15663-27-1 ]
[ 490-79-9 ]
C₇H₁₀N₂O₄Pt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
53%	With sodium carbonate; silver nitrate; In N,N-dimethyl-formamide; at 20℃; for 24h;Darkness;	Cisplatin (150mg), AgNO3 (170mg), gentisic acid (77mg) and Na2C03 (35.3mg) were added to a round bottom flask followed by 15ml of DMF and stirred for 24 h at room temperature in the dark. The precipitate was removed by centrifugation. After the filtrate was concentrated, 50 ml of ethyl acetate was added and the mixture was washed three times with 50 ml of 0.1 M Na2CO3 and washed with water three times. The ethyl acetate layer was collected and dried over anhydrous sodium sulfate overnight. Filtration, the filtrate with methanol: dichloromethane = 1: 9 eluent, silica gel column chromatography to obtain <strong>[15663-27-1]cisplatin</strong> - gentisic acid complex, a yield of 53%, the structural formula is shown in the formula 24..

Reference： [1]Patent: CN107296794,2017,A .Location in patent: Paragraph 0104-0106

78
[ 15663-27-1 ]
[ 15722-48-2 ]
C₁₄H₁₈N₆O₆Pt₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
49%	With sodium carbonate; silver nitrate; In N,N-dimethyl-formamide; at 20℃; for 24h;Darkness;	<strong>[15663-27-1]cisplatin</strong> (150 mg), AgN03 (170 mg), olsalazine (75.6 mg) and Na2C03 (70.6 mg) were added to a round bottom flask followed by 15 ml of DMF and stirred for 24 h at room temperature in the dark. The precipitate was removed by centrifugation. After the filtrate was concentrated, 50 ml of ethyl acetate was added and the mixture was washed three times with 50 ml of 0.1 M Na2CO3 and washed with water three times. The ethyl acetate layer was collected and dried over anhydrous sodium sulfate overnight. Filtration and the filtrate was eluted with methanol: dichloromethane = 1: 9 and separated by silica gel column chromatography to give the <strong>[15663-27-1]cisplatin</strong>-olsalazine complex in 49% yield, as shown in Formula 25

Reference： [1]Patent: CN107296794,2017,A .Location in patent: Paragraph 0107-0109

79
[ 15663-27-1 ]
[ 53597-27-6 ]
C₂₅H₂₃N₃O₃Pt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
53%	With sodium carbonate; silver nitrate; In N,N-dimethyl-formamide; at 20℃; for 24h;Darkness;	Add <strong>[15663-27-1]cisplatin</strong> (150mg), AgN03 (170mg), fendosal(190.7mg) and Na2C03 (35.3mg) into a round bottom flask, then add 15ml of DMF and stir at room temperature for 24h. The precipitate was removed by centrifugation. After the filtrate was concentrated, 50 ml of ethyl acetate was added and the mixture was washed three times with 50 ml of 0.1 M Na2CO3 and washed with water three times. The ethyl acetate layer was collected and dried over anhydrous sodium sulfate overnight. Filtration, the filtrate with methanol: dichloromethane = 1: 9 eluent, silica gel column chromatography to obtain <strong>[15663-27-1]cisplatin</strong> - Fendalu complex, a yield of 53%, the structural formula is shown in formula 26..

Reference： [1]Patent: CN107296794,2017,A .Location in patent: Paragraph 0110-0112

80
[ 15663-27-1 ]
[ 67-43-6 ]
potassium hydroxide [ No CAS ]
C₁₄H₃₀N₇O₁₀Pt₂^(1-)*K⁽¹⁺⁾ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In water; at 20℃; for 65h;pH 7.5;	53.28 mg of DTPA and 80 mL of pure water were added to the reaction flask, the pH was adjusted to 7.5 with 0.1 M KOH, and 81.28 mg of CDDP was added. The reaction was stirred at room temperature for 65h, dialyzed against a dialysis bag with molecular weight cut-off of 500 for 48h, and the liquid was collected and stored in a refrigerator at 4 C.

Reference： [1]Patent: CN103396456,2016,B .Location in patent: Paragraph 0072; 0073; 0078; 0083; 0088; 0093; 0098

81
[ 15663-27-1 ]
N1-anthracen-9-ylmethylethane-1,2-diamine dihydrochloride [ No CAS ]
C₁₇H₂₄N₄Pt⁽²⁺⁾*2Cl^(1-) [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
71.3%		(6) Synthesis of Pt (NH 3) 2 (AtC 2) Cl 2AtC 2 .2 HCl 0.42 g (1.3 mmol)Was dissolved in 10 ml of H 2 0 and 0.20 g (5 mmol) of NaOH was added. 20 mL of CHCl 3 was added to extract AtC 3, evaporated and dissolved in 10 mL of EtOH.To this was added a solution of 0.15 g (0.5 mmol) of Pt (NH 3) 2 Cl 2 in 5 ml of H 2 O, stirred at 60 C. for 24 hours, evaporated until the filtrate reached 1 to 2 ml, reprecipitated with acetone, Was collected by suction filtration, washed, and dried.Yield: 0.212 gYield: 71.3%

Reference： [1]Patent: JP2018/135297,2018,A .Location in patent: Paragraph 0063

82
cis-diaminediiodoplatinum(II) [ No CAS ]
[ 7647-14-5 ]
[ 15663-27-1 ]

Yield	Reaction Conditions	Operation in experiment
61.7%	With silver nitrate; In N,N-dimethyl acetamide; water; at 60℃;Darkness;	(2) Synthesis of cis-Pt (NH 3) 2 Cl 20.68 g (4.0 mmol) of AgNO 3 was dissolved in 80 ml of H 2 O,A solution of 10 ml of dimethylacetamide in which 0.96 g (2.0 mmol) of cis-Pt (NH 3) 2 I 2 was dissolved was added, and the mixture was shielded from light and stirred overnight. The solution was filtered to remove AgI and washed with 1 M2 mL of NaCl was added,And the mixture was stirred at 60 C. overnight.The produced yellow powder was collected by filtration,With a lot of cold waterAnd washed.Yield: 0.374 gYield: 61.7%

Reference： [1]Patent: JP2018/135297,2018,A .Location in patent: Paragraph 0059

83
[ 15663-27-1 ]
tetrapyridine tin porphyrin [ No CAS ]
C₄₀H₄₈Cl₄N₁₆Pt₄Sn⁽⁴⁺⁾ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
62.3%		The <strong>[15663-27-1]cisplatin</strong>-containing prodrug ligand (PtH6N2Cl2, 38.7 mg, 0.129 mmol) was dissolved in 3 mL of N,N-dimethylformamide, silver nitrate (22 mg, 0.129 mmol) was added, and the reaction was carried out at 60 degrees for 24 hours. The precipitate was removed by filtration; the tin porphyrin core (24.8 mg, 0.032 mmol) was suspended in 3 mL of N,N-dimethylformamide, and the above reaction solution was added dropwise to the suspension, nitrogen.The reaction was carried out under gas protection for 36 hours. Precipitation with diethyl ether, filtration, washed with cold methanol, chloroform and diethyl ether to afford title product.

Reference： [1]Patent: CN109251206,2019,A .Location in patent: Paragraph 0037; 0038; 0039

84
[ 15663-27-1 ]
[ 72-48-0 ]
C₁₄H₁₂N₂O₄Pt [ No CAS ]

Reference： [1]Applied Organometallic Chemistry,2020,vol. 34

85
[ 15663-27-1 ]
[ 75-04-7 ]
[ 64538-67-6 ]

Yield	Reaction Conditions	Operation in experiment
45%		General procedure: The general synthetic procedure for the mixed transplatinum(II) complexes has been reported by Wilson and Lippard [4]. Cisplatin (100 mg, 0.333 mmol) was suspended in water (2 mL), and 8 equivalents of the appropriate alkylamine ligand were added. The resulting mixture was heated at 90 C until the solution became colourless. After the solution was cooled to room temperature, it was then treated with 37% (v/v) concentrated HCl (2.5 mL) followed by stirring and heating at 90 C for 48 h. The resulting yellow solution was placed in an iced bath to induce precipitation of the appropriate trans-platinum(II) complex which was recovered by filtration, washed intensively with water and diethyl ether, and air-dried at room temperature. tPt2 yield: 49 mg (45%). 1H NMR (500 MHz, DMF-d7), delta(ppm): 1.26 (t, 3H); 2.73 (sextet 2H); 3.72 (s, 3H), 4.38 (s, 2H). 195Pt NMR (107 MHz, DMF-d7), delta(ppm): - 2165.7. TOF MS/ES+, m/z: (M + Na)+: 350.9 (C2H8NaN2PtCl2, species). Anal. Cal for C2H10N2PtCl2: N, 8.54; C, 7.32; H, 3.07. Found: N, 8.50; C, 7.00; H, 2.86.

Reference： [1]Transition Metal Chemistry,2020

86
[ 107-10-8 ]
[ 15663-27-1 ]
trans-Pt(NH3)(NH2C3H7)Cl2 [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
80%		General procedure: The general synthetic procedure for the mixed transplatinum(II) complexes has been reported by Wilson and Lippard [4]. Cisplatin (100 mg, 0.333 mmol) was suspended in water (2 mL), and 8 equivalents of the appropriate alkylamine ligand were added. The resulting mixture was heated at 90 C until the solution became colourless. After the solution was cooled to room temperature, it was then treated with 37% (v/v) concentrated HCl (2.5 mL) followed by stirring and heating at 90 C for 48 h. The resulting yellow solution was placed in an iced bath to induce precipitation of the appropriate trans-platinum(II) complex which was recovered by filtration, washed intensively with water and diethyl ether, and air-dried at room temperature.

Reference： [1]Transition Metal Chemistry,2020

87
[ 15663-27-1 ]
[ 109-73-9 ]
trans-Pt(NH3)(NH2C4H9)Cl2 [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
75%		General procedure: The general synthetic procedure for the mixed transplatinum(II) complexes has been reported by Wilson and Lippard [4]. Cisplatin (100 mg, 0.333 mmol) was suspended in water (2 mL), and 8 equivalents of the appropriate alkylamine ligand were added. The resulting mixture was heated at 90 C until the solution became colourless. After the solution was cooled to room temperature, it was then treated with 37% (v/v) concentrated HCl (2.5 mL) followed by stirring and heating at 90 C for 48 h. The resulting yellow solution was placed in an iced bath to induce precipitation of the appropriate trans-platinum(II) complex which was recovered by filtration, washed intensively with water and diethyl ether, and air-dried at room temperature.

Reference： [1]Transition Metal Chemistry,2020

88
[ 15663-27-1 ]
[ 110-58-7 ]
trans-Pt(NH3)(NH2C5H11)Cl2 [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
55%		General procedure: The general synthetic procedure for the mixed transplatinum(II) complexes has been reported by Wilson and Lippard [4]. Cisplatin (100 mg, 0.333 mmol) was suspended in water (2 mL), and 8 equivalents of the appropriate alkylamine ligand were added. The resulting mixture was heated at 90 C until the solution became colourless. After the solution was cooled to room temperature, it was then treated with 37% (v/v) concentrated HCl (2.5 mL) followed by stirring and heating at 90 C for 48 h. The resulting yellow solution was placed in an iced bath to induce precipitation of the appropriate trans-platinum(II) complex which was recovered by filtration, washed intensively with water and diethyl ether, and air-dried at room temperature.

Reference： [1]Transition Metal Chemistry,2020

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

CAS No. :	15663-27-1	MDL No. :	MFCD00011623
Formula :	Cl₂H₆N₂Pt	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	DQLATGHUWYMOKM-UHFFFAOYSA-L
M.W :	300.05	Pubchem ID :	2767
Synonyms :	cis-Platinum;CDDP;CACP;cis-Diamminedichloroplatinum;DDP;cis DDP;cis-diamminedichloroplatinum II;NSC 119875;cis-Diaminodichloroplatinum

Signal Word:	Danger	Class:	6.1
Precautionary Statements:	P501-P263-P260-P270-P202-P201-P264-P280-P337+P313-P305+P351+P338-P308+P311-P332+P313-P301+P310+P330-P405	UN#:	3288
Hazard Statements:	H300-H316-H319-H360-H362-H370-H372-H340-H350	Packing Group:	Ⅱ
GHS Pictogram:

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

[ CAS No. 15663-27-1 ] {[proInfo.proName]}

Quality Control of [ 15663-27-1 ]

Related Doc. of [ 15663-27-1 ]

Product Details of [ 15663-27-1 ]

Safety of [ 15663-27-1 ]

Application In Synthesis of [ 15663-27-1 ]

[ 15663-27-1 ] Synthesis Path-Upstream 1~2

[ 15663-27-1 ] Synthesis Path-Downstream 1~88

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry